Cardinal Health (NYSE:CAH) has been identified as one of the best 52-week high stocks to buy, according to analysts. Just recently, on June 10, analysts at TD Cowen reiterated a Buy rating and maintained a price target of $162 on the stock. This reaffirmation of confidence in Cardinal Health has sparked interest among investors looking for promising opportunities in the market.
The analysts have high expectations for Cardinal Health, anticipating an increase in its long-term pharmaceutical profit guidance from 5% to 7%, up from a previous guidance of 4% to 6%. Additionally, the company is projected to introduce preliminary adjusted earnings per share guidance ranging from $9.15 to $9.45. These positive outlooks indicate a strong potential for growth and profitability for Cardinal Health in the foreseeable future.
Furthermore, TD Cowen analyst also anticipates that Cardinal Health will provide insights on how other segment businesses will contribute 18% of adjusted operating income. The company has recently entered into a distribution agreement with Citious Oncology to support the launch of FDA-approved immunotherapy LYMPHIR, showcasing its commitment to expanding its reach and offerings in the healthcare industry.
Cardinal Health, a global healthcare company, is known for its distribution of pharmaceuticals and specialty products, as well as its manufacturing and distribution of medical and laboratory products. With a solid reputation in the healthcare sector, Cardinal Health is positioned as a key player in the industry, driving innovation and delivering essential products and services to customers worldwide.
While Cardinal Health presents itself as an attractive investment opportunity, some investors may be looking towards AI stocks for even greater upside potential and reduced downside risk. For those seeking undervalued AI stocks with significant growth prospects, a free report on the best short-term AI stock may offer valuable insights and opportunities.
In conclusion, Cardinal Health continues to be a strong contender in the healthcare market, with analysts expressing confidence in its future performance and growth potential. As investors weigh their options in the market, Cardinal Health stands out as a promising choice for those seeking to capitalize on the evolving landscape of healthcare and pharmaceuticals.
